The Study of Minocycline for Negative and Cognitive Symptoms in Schizophrenia

Central South University

Status and phase

Completed

Phase 4

Conditions

Schizophrenia

Treatments

Drug: minocycline

Drug: placebo

Study type

Interventional

Funder types

Other

Identifiers

NCT01493622

2010LL02 (Other Identifier)

CSU-2010-PSY

Details and patient eligibility

About

The purpose of this study is to determine whether minocycline are effective in the treatment of negative and cognitive symptoms in schizophrenia.

Full description

Immune-related disorders have been hypothesized as etiological factors in schizophrenia.Minocycline is a second-generation tetracycline that exerts anti-inflammatory and antimicrobial effects while having a distinct neuroprotective profile.This study was performed as a double-blind, placebocontrolled,randomized evaluation of Second generation antipsychotics(SGA) and minocycline versus SGA and placebo.

Enrollment

78 patients

Sex

All

Ages

18 to 40 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

male and female,were aged 18-40 years
were currently diagnosed with DSM-IV schizophrenia
were able to comprehend the cognition test
patients or guardian signed informed consent,were able to comprehend the procedure and aims of the study,agreed to join the study
patient's current antipsychotic medication regimen must be stable
must be in a stable living arrangement

Exclusion criteria

had ever been hypersensitivity to minocycline or tetracycline;
had acute,unstable,significant,or untreated medical illness besides schizophrenia
were pregnant or breast-feeding;
had a DSM-IV diagnosis of substance abuse or dependency;
had a tendency to suicide or Violence,self-harm;
had taken immunosuppressive agents in the preceding 3 months before study entry;
had influenza or fever in the preceding 2 weeks before study entry;
had a DSM-IV diagnosis of emotional psychosis,Mental retardation,etc.
has suicidal attempts or ideation or violent behavior within the last 12 months
patient has mental retardation or severe organic brain syndromes
treatment with Electroconvulsive Therapy (ECT) within 6 months prior to screening